TOP TEN perturbations for 38605_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38605_at
Selected probe(set): 206790_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38605_at (206790_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
sirolimus study 6 (light) / sirolimus study 6 (heavy)
Relative Expression (log2-ratio):2.7985477Number of Samples:3 / 3
| Experimental | sirolimus study 6 (light) |
| Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the light polysome fraction. ATC code: | |
| Control | sirolimus study 6 (heavy) |
| Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the heavy polysome fraction. ATC code: |
kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample
Relative Expression (log2-ratio):-2.597846Number of Samples:3 / 3
| Experimental | kidney transplantation study 16 (2 week) |
| CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal natural killer cell (CD56+) sample |
| CD56+ natural killer cell samples derived from healthy control subjects. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Relative Expression (log2-ratio):-2.3964653Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). |
nonspecific orbital inflammatory disease study 1 (lacrimal gland tissue) / normal lacrimal gland tissue
Relative Expression (log2-ratio):-2.3488913Number of Samples:42 / 7
| Experimental | nonspecific orbital inflammatory disease study 1 (lacrimal gland tissue) |
| Lacrimal gland tissue samples obtained from patients who suffered from nonspecific orbital inflammatory disease (NSOI). Biopsies were formalin-fixed and paraffin-embedded. | |
| Control | normal lacrimal gland tissue |
| Normal lacrimal gland tissue samples. The control tissue was obtained during surgery on eyes with non-inflamed orbits, such as blepharoplasties and enucleations. Biopsies were formalin-fixed and paraffin-embedded. |
septic shock study 3 (D3; non-survivor) / normal blood sample
Relative Expression (log2-ratio):2.1219034Number of Samples:9 / 22
| Experimental | septic shock study 3 (D3; non-survivor) |
| Blood samples from patients (non-survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)
Relative Expression (log2-ratio):2.1071672Number of Samples:2 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, dedifferentiated liposarcoma of the soft tissue (subcutaneously implanted). |
septic shock study 3 (D2; non-survivor) / normal blood sample
Relative Expression (log2-ratio):2.0868874Number of Samples:8 / 22
| Experimental | septic shock study 3 (D2; non-survivor) |
| Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.0105658Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (novicida) |
| Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
expO kidney cancer study 1 (neoplasm, malignant; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):-1.9994011Number of Samples:2 / 4
| Experimental | expO kidney cancer study 1 (neoplasm, malignant; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm. | |
| Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
breast cancer study 5 / normal organelle sample
Relative Expression (log2-ratio):1.9343519Number of Samples:20 / 12
| Experimental | breast cancer study 5 |
| Breast non-BLC (sporadic basal-like cancer) tumor samples. | |
| Control | normal organelle sample |
| Normal organelle samples. |